{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-study#webpage",
"url": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-study",
"name": "Serving as an Extended Safety Partner for an Emerging Biotech’s Vaccine Study",
"description": "This Fortrea case study explores how a biotech molecule was guided through the product development lifecycle using integrated clinical development strategy, regulatory consulting, and cross-functional operational planning. The study involved a biotech sponsor developing a cardiometabolic therapy that required coordinated support across regulatory strategy, Phase I PK/PD studies, Phase II clinical development, and Phase III clinical trial preparation. The case study highlights challenges related to development continuity, transition management between clinical phases, patient recruitment planning, and reducing operational white space throughout the biotech clinical development process. Fortrea provided strategic guidance across regulatory, clinical, medical, market access, and commercial planning activities to support data-driven decision-making and long-term program execution. By integrating product development lifecycle strategy with clinical development operations, regulatory consultancy, and phase-to-phase transition planning, the approach strengthened continuity across biotech development activities and supported progression toward late-stage clinical milestones."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Serving as an Extended Safety Partner for an Emerging Biotech’s Vaccine Study",
"item": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-study"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-study#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/serving-extended-safety-partner-emerging-biotechs-vaccine-study#webpage"
},
"headline": "Extended Vaccine Safety Surveillance and Pharmacovigilance Solutions | Fortrea Case Study",
"description": "This Fortrea case study explores how a biotech molecule was guided through the product development lifecycle using integrated clinical development strategy, regulatory consulting, and cross-functional operational planning. The study involved a biotech sponsor developing a cardiometabolic therapy that required coordinated support across regulatory strategy, Phase I PK/PD studies, Phase II clinical development, and Phase III clinical trial preparation. The case study highlights challenges related to development continuity, transition management between clinical phases, patient recruitment planning, and reducing operational white space throughout the biotech clinical development process. Fortrea provided strategic guidance across regulatory, clinical, medical, market access, and commercial planning activities to support data-driven decision-making and long-term program execution. By integrating product development lifecycle strategy with clinical development operations, regulatory consultancy, and phase-to-phase transition planning, the approach strengthened continuity across biotech development activities and supported progression toward late-stage clinical milestones.",
"genre": "Case Study",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-09-04",
"dateModified": "2025-09-04",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-09/case-study-extended-safety-partner-vaccine.pdf",
"encodingFormat": "application/pdf"
}
}
]
}